Clinical Trial Update: Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD) [Phase 1]

View source ↗

Summary

Phase I single-dose escalation safety study of prGCD (human glucocerebrosidase) in Gaucher disease; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease

Drugs mentioned

• prGCD (human glucocerebrosidase) (human glucocerebrosidase)

Snippet

Sponsor: Protalix | Conditions: Gaucher Disease | Phase 1 | Status: COMPLETED